Organogenesis Holdings Inc.
NASDAQ:ORGODrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $110.75M
- Beta
- 1.33
- P/E (TTM)
- -1086.7
- EPS (TTM)
- -$0.00
Volume 0.86M
Average 1.49M
ORGO Net Income
Bottom-line profit after all expenses, interest, and taxes.
Organogenesis Holdings Inc.NASDAQ: ORGO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$56.16M, compared with -$18.84M a year earlier. Trailing-twelve-month net income was -$284K. Over 3 fiscal years it compounded at +33.6% a year.
Context
- Net income amounted to 6.6% of revenue in FY2025, up 6.4 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$186.26M (-603.0%) for the fiscal year ending Dec 2026, a slowdown from the +4201.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$56.16M-228.5% QoQ
- Last fiscal yearDec 2025
- $37.03M+4201.0% YoY
- LTMMar 2026
- -$284K+98.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -198.0% | -380.7% | -182.7 pp |
| 1 year | +4201.0% | -603.0% | -4804.0 pp |
| 3-year CAGR | +33.6% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- 37.03M USD
- Year-over-year change
- +4201.0%
- 4-year CAGR
- -20.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.03M | +4201.0% |
| FY2024 | 2024-12-31 | 861K | -82.6% |
| FY2023 | 2023-12-31 | 4.95M | -68.2% |
| FY2022 | 2022-12-31 | 15.53M | -83.5% |
| FY2021 | 2021-12-31 | 94.2M | — |
Net Income vs competitors
How ORGO compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +98.2% is the highest of 11, against a peer median of +16.2%.
- Net income amounts to 0.1% of revenue for ORGO, versus a peer median of 9.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.26M USD | -58.2% | -11.8% | 21.6% | |
| LTM Mar 2026 | -$284K USD | +98.2% | +33.6% | 0.1% | |
| LTM Mar 2026 | -$7.42M USD | +95.2% | — | 1.8% | |
| LTM Mar 2026 | -$8.6M USD | +93.5% | — | 1.3% | |
| LTM Mar 2026 | -CA$10.98M CAD | +89.7% | — | 1.2% | |
| LTM Mar 2026 | -$14.98M USD | +9.6% | — | — | |
| LTM Feb 2026 | -$31.39M USD | +24.2% | — | 10.0% | |
| LTM Mar 2026 | -$43.42M USD | +22.7% | — | 14.4% | |
| LTM Mar 2026 | -$68.17M USD | -23.5% | — | — | |
| LTM Apr 2026 | -$82.7M USD | -96.9% | — | 9.6% | |
| LTM Mar 2026 | -$219.03M USD | -7.8% | — | 345.0% | |
| Peer median (excluding ORGO) | — | +16.2% | -11.8% | 9.8% | |
Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 467.36M | 450.89M | 433.14M | 482.04M | 563.03M |
| Cost of Revenue | 114.2M | 105.02M | 106.48M | 115.74M | 137.52M |
| Gross Profit | 353.16M | 345.87M | 326.66M | 366.3M | 425.51M |
| Gross Margin | 75.6% | 76.7% | 75.4% | 76.0% | 75.6% |
| Research & Development | 30.74M | 39.76M | 44.38M | 50.27M | 44.54M |
| Selling, General & Admin | 250.2M | 283.81M | 269.75M | 294.51M | 326.24M |
| Operating Expenses | 280.94M | 323.57M | 314.13M | 367.59M | 369.64M |
| Depreciation & Amortization | 16.68M | 18.03M | 23.45M | 17.03M | 26.94M |
| EBITDA | 87M | 40.32M | 36.03M | 15.76M | 73.91M |
| EBITDA Margin | 18.6% | 8.9% | 8.3% | 3.3% | 13.1% |
| Operating Income | 72.22M | 22.3M | 12.53M | (1.28M) | 55.87M |
| Operating Margin | 15.5% | 4.9% | 2.9% | -0.3% | 9.9% |
| Interest Income | 0 | 0 | 0 | 0 | 2.28M |
| Interest Expense | 7.24M | 2.01M | 2.19M | 1.54M | 0 |
| Other Income / Expenses | (9.13M) | (2.02M) | (2.13M) | (1.52M) | (8.9M) |
| Income Before Tax | 63.09M | 20.28M | 10.39M | (2.81M) | 46.97M |
| Pre-Tax Margin | 13.5% | 4.5% | 2.4% | -0.6% | 8.3% |
| Income Tax Expense | (31.12M) | 4.75M | 5.45M | (3.67M) | 9.94M |
| Net Income | 94.2M | 15.53M | 4.95M | 861K | 37.03M |
| Net Margin | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% |
| EPS (Basic) | 0.73 | 0.12 | 0.04 | (0.01) | 0.16 |
| EPS (Diluted) | 0.70 | 0.12 | 0.04 | (0.01) | 0.15 |
| Weighted Avg Shares | 128.33M | 130.07M | 131.23M | 131.67M | 126.74M |
| Weighted Avg Shares (Diluted) | 133.66M | 132.38M | 132.75M | 131.67M | 130.25M |
Organogenesis Holdings Inc.
NASDAQ:ORGO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.